Co-Diagnostics Sales of New Multi-Viral Test Imminent Post CE Mark
Back to Newsroom
Mentioned in this Article

Co-Diagnostics Sales of New Multi-Viral Test Imminent Post CE Mark

Wednesday, March 13, 2019 8:30 AM
Share this article now
Company Update,Product Announcements

NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Co-Diagnostics, Inc., (NASDAQ: CODX), expects to immediately begin commercializing their newly-CE marked test for Zika, dengue and chikunguna, according to news released last week.

The Co-Diagnostics release announced that their new Logix Smart ZDC test meets the essential requirements of the European Community's In-Vitro Diagnostic Medical Device Directive, allowing immediate export and sales of the product to markets that accept a CE mark as valid IVD regulatory approval, with the expectation that additional sales and distribution opportunities will be created following the granting of this approval across their target markets. These include several countries south of the US border in which they already have distribution agreements in place, and where local product registration requirements may already be pending.

Last week's announcement stated that the design, development, and validation of test was completed from start to finish in under 6 months, including the entire regulatory approval process. Taking a test from concept to commercialization in that amount of time certainly underscores their mission to applying their own platform for efficient, economical product development.

This multiplex test that identifies several targets at once also appears to be the most sophisticated of all Co-Diagnostics products approved for regulatory approval to date. Company CEO described this ''highly-specific diagnostic for three harmful diseases at once'' as being made possible thanks to the company's ''patented CoPrimer design platform enabling a massive reduction in false positives, which is especially important - but notoriously more difficult - in multiplexed assays of related pathogens.''

With the approval of this test, the company has released three products with CE markings since July 2018. If their infectious disease pipeline and sales prospects continue at this rate, their fundamentals alone will soon make the $2 price target set by H.C. Wainwright (whose analyst recently initiated coverage of CODX with a Buy rating) seem conservative.

About The Wall Street Club:

The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC writes about stocks in both free and paid content. WSC accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information.


The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the Wall Street Club may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words ''anticipate,'' ''intend,'' ''estimate,'' ''believe,'' ''expect,'' ''plans,'' ''should,'' ''potential,'' ''forecast,'' and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at Investing in securities is speculative and carries risk.

Press Contact:

The Wall Street Club
[email protected]

SOURCE: Co-Diagnostics, Inc.

Co-Diagnostics, Inc.
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: